⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Naiji Pharmaceutical Technology (Hangzhou) Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Naiji Pharmaceutical Technology (Hangzhou) Co., Ltd. is a Chinese biotechnology company focused on medical research, experimental development, and pharmaceutical technology. The company specializes in gene therapy and viral vector technologies, including the development of AAV capsid protein mutants and recombinant adeno-associated virus production methods.
Recognized as a municipal-level quasi-unicorn enterprise and a national-level technology-based small and medium-sized enterprise, the company maintains research capabilities in molecular biology and software systems for DNA compound information sharing. It operates primarily within the Hangzhou biomedical industry cluster.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2021
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery
Modalities:Viral vectors, AAV
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Xiao Wenxue - Legal Representative
LINKS
Website:nikebio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Naiji Pharmaceutical Technology (Hangzhou) Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.